SCHEMBL22957447

SCHEMBL22957447

CCOC(=O)c1sc2nc(Cl)ccc2c1N

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.67
SMN1; SMN2 Q16637 7/20 0.67
NPC1 O15118 6/20 0.67
RAB9A P51151 6/20 0.67
HPGD P15428 5/20 0.67
MAPT P10636 6/20 0.61
NFKB1 P19838 2/20 0.61
NFKB2 Q00653 2/20 0.61
RELA Q04206 2/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
POLB P06746 1/20 0.61
ALDH1A1 P00352 9/20 0.53
CASP1 P29466 2/20 0.53
HSD17B10 Q99714 2/20 0.53
GAA P10253 2/20 0.53
ATM Q13315 2/20 0.53
GLA P06280 1/20 0.53
CASP7 P55210 1/20 0.53
MAPK1 P28482 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29707339 0.86 KDM4E (0.70) KDM4ESMN1; SMN2NPC1RAB9AHPGD
SCHEMBL3494383 0.86 KDM4E (0.70) KDM4ESMN1; SMN2NPC1RAB9AHPGD
SCHEMBL31221733 0.85 KDM4E (0.59) KDM4ESMN1; SMN2NPC1RAB9AHPGD
SCHEMBL7050857 0.85 KDM4E (0.59) KDM4ESMN1; SMN2NPC1RAB9AHPGD
SCHEMBL22957547 0.84 KDM4E (0.67) KDM4ESMN1; SMN2NPC1RAB9AHPGD
SCHEMBL25808573 0.83 KDM4E (0.65) KDM4ESMN1; SMN2NPC1RAB9AHPGD
SCHEMBL5858952 0.82 KDM4E (0.64) KDM4ESMN1; SMN2NPC1RAB9AHPGD
SCHEMBL26784104 0.82 ADORA2A (0.65) KDM4ESMN1; SMN2NPC1RAB9AHPGD
SCHEMBL3493480 0.81 KDM4E (0.63) KDM4ESMN1; SMN2NPC1RAB9AHPGD
SCHEMBL8091104 0.79 LIMK1 (0.51) KDM4ESMN1; SMN2NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3414252-B1 THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO HEALTH INC (US) 2022-07-06 EP disclosed
CN-109071560-B Thienopyridine carboxamides as ubiquitin-specific protease inhibitors 瓦洛健康公司 2022-01-14 CN disclosed
US-10913753-B2 Thienopyridine carboxamides as ubiquitin-specific protease inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-02-09 US disclosed
US-10913753-B2 Thienopyridine carboxamides as ubiquitin-specific protease inhibitors VALO EARLY DISCOVERY, INC. (US) 2021-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10913753-B2 Thienopyridine carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 KDM4E 636/4885SMN1; SMN2 3449/4885NPC1 4780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.